Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Work In Process (2023 - 2024)

Harmony Biosciences Holdings (HRMY) has disclosed Work In Process for 2 consecutive years, with $3.5 million as the latest value for Q4 2024.

  • Quarterly Work In Process rose 72.72% to $3.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2024, up 72.72% year-over-year, with the annual reading at $3.5 million for FY2024, 72.72% up from the prior year.
  • Work In Process hit $3.5 million in Q4 2024 for Harmony Biosciences Holdings, up from $2.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.5 million in Q4 2024 to a low of $1.7 million in Q2 2024.